Correlation Between Virpax Pharmaceuticals and EnGene Holdings

Can any of the company-specific risk be diversified away by investing in both Virpax Pharmaceuticals and EnGene Holdings at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virpax Pharmaceuticals and EnGene Holdings into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Virpax Pharmaceuticals and enGene Holdings Common, you can compare the effects of market volatilities on Virpax Pharmaceuticals and EnGene Holdings and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virpax Pharmaceuticals with a short position of EnGene Holdings. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virpax Pharmaceuticals and EnGene Holdings.

Diversification Opportunities for Virpax Pharmaceuticals and EnGene Holdings

-0.33

Correlation Coefficient

Virpax Pharmaceuticals  EnGene Holdings

Very good diversification

The 3 months correlation between Virpax and EnGene is -0.33. Overlapping area represents the amount of risk that can be diversified away by holding Virpax Pharmaceuticals and enGene Holdings Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on enGene Holdings Common and Virpax Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virpax Pharmaceuticals are associated (or correlated) with EnGene Holdings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of enGene Holdings Common has no effect on the direction of Virpax Pharmaceuticals i.e., Virpax Pharmaceuticals and EnGene Holdings go up and down completely randomly.

Pair Corralation between Virpax Pharmaceuticals and EnGene Holdings

Given the investment horizon of 90 days Virpax Pharmaceuticals is expected to under-perform the EnGene Holdings. In addition to that, Virpax Pharmaceuticals is 1.42 times more volatile than enGene Holdings Common. It trades about -0.17 of its total potential returns per unit of risk. enGene Holdings Common is currently generating about 0.06 per unit of volatility. If you would invest  665.00  in enGene Holdings Common on September 12, 2024 and sell it today you would earn a total of  86.00  from holding enGene Holdings Common or generate 12.93% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	98.46%
Values	Daily Returns

Virpax Pharmaceuticals  vs.  enGene Holdings Common

Virpax Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Virpax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

enGene Holdings Common

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in enGene Holdings Common are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very weak technical and fundamental indicators, EnGene Holdings displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Virpax Pharmaceuticals and EnGene Holdings

The main advantage of trading using opposite Virpax Pharmaceuticals and EnGene Holdings positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virpax Pharmaceuticals position performs unexpectedly, EnGene Holdings can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EnGene Holdings will offset losses from the drop in EnGene Holdings' long position.

The idea behind Virpax Pharmaceuticals and enGene Holdings Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..